Genepod Therapeutics

Genepod Therapeutics was a Swedish biotechnology company focused on gene therapy for Parkinson's disease and related dopamine-deficiency disorders. The company appears to have centered its work on AAV-based viral vector constructs designed to enable continuous neuronal DOPA synthesis in vivo through delivery of tyrosine hydroxylase and GTP cyclohydrolase 1. Publicly visible evidence suggests a very narrow pipeline built around this core program and associated intellectual property rather than a broad multi-asset platform. Available company-registry and business-directory traces indicate the company was small, private, and based in Falun, Sweden. The most recent accessible signals point to the company no longer being active as an operating biotech company.